These changes correlated with marked normalization of structural, functional and biochemical abnormalities in the aorta, suggesting that although the AAV-mediated gene therapy strategy used to correct LH1 expression in this study was not sufficient to completely alleviate dissecting AAA, gene therapy could be combined with conventional interventions to provide a potential better therapeutic strategy for AAA patients. The gene discussed is PLOD1; the disease is triple-A syndrome.